EBSCO Logo
Connecting you to content on EBSCOhost
Results
Title

A Comparison between Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Eradication in Patients with Uremia: A Randomized Clinical Trial.

Authors

Makhlough, Atieh; Fakheri, Hafez; Hojati, Samaneh; Hosseini, Vahid; Bari, Zohreh

Abstract

BACKGROUND The prevalence of peptic ulcer disease in hemodialysis patients is more than the general population. They are also more prone to complications including upper gastrointestinal bleeding. The aim of this study was to compare the efficacy of 14 days hybrid regimen with 14 days triple therapy for Helicobacter pylori (H. pylori) eradication in hemodialysis patients. METHODS Forty hemodialysis patients with naïve H.pylori infection were randomized to receive either hybrid regimen (pantoprazole 40 mg + amoxicillin 500 mg, both twice a day during the first 7 days, followed by pantoprazole 40 mg + amoxicillin 500 mg + clarithromycin 500 mg + tinidazole 500 mg, all twice a day, for the second 7 days, or standard triple therapy including pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 500 mg, all twice a day for 14 days. H.pylori eradication was assessed by fecal H.pylori antigen test 8 weeks after the treatment. RESULTS All the patients completed the study. According to both intention to treat and per-protocol analyses, H.pylori eradication rates were 100% (95% confidence interval (CI): 100) in those who received hybrid therapy and 70% (95% CI: 69.4 - 70.8) in those who were treated by standard triple therapy (p=0.02). Severe adverse effects were not reported by any patient; however, mild adverse effects were more frequent in those who received standard triple therapy (p<0.05). CONCLUSION Hybrid regimen could achieve ideal H.pylori eradication rates with low rates of adverse effects.

Subjects

AMOXICILLIN; CLARITHROMYCIN; PROTON pump inhibitors; IMIDAZOLES; HELICOBACTER diseases; COMBINATION drug therapy; CONFIDENCE intervals; HEMODIALYSIS patients; STATISTICAL sampling; UREMIA; RANDOMIZED controlled trials; TREATMENT effectiveness; PREVENTION; THERAPEUTICS

Publication

Middle East Journal of Digestive Diseases, 2016, Vol 8, Issue 1, p39

ISSN

2008-5230

Publication type

Academic Journal

DOI

10.15171/mejdd.2016.05

EBSCO Connect | Privacy policy | Terms of use | Copyright | Manage my cookies
Journals | Subjects | Sitemap
© 2025 EBSCO Industries, Inc. All rights reserved